IN2015DN03998A - - Google Patents

Info

Publication number
IN2015DN03998A
IN2015DN03998A IN3998DEN2015A IN2015DN03998A IN 2015DN03998 A IN2015DN03998 A IN 2015DN03998A IN 3998DEN2015 A IN3998DEN2015 A IN 3998DEN2015A IN 2015DN03998 A IN2015DN03998 A IN 2015DN03998A
Authority
IN
India
Prior art keywords
medicaments
medicament
substituents
salt
compound
Prior art date
Application number
Other languages
English (en)
Inventor
Edgar Jacoby
Juergen Reinhardt
Niko Schmiedeberg
Carsten Spanka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015DN03998(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN03998A publication Critical patent/IN2015DN03998A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inorganic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
IN3998DEN2015 2012-12-13 2013-12-12 IN2015DN03998A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13
PCT/IB2013/060859 WO2014091446A1 (fr) 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones utilisés en tant que suppresseurs de mutation non-sens

Publications (1)

Publication Number Publication Date
IN2015DN03998A true IN2015DN03998A (fr) 2015-10-02

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3998DEN2015 IN2015DN03998A (fr) 2012-12-13 2013-12-12

Country Status (24)

Country Link
US (2) US9649314B2 (fr)
EP (1) EP2931282B1 (fr)
JP (1) JP6076498B2 (fr)
KR (1) KR101760586B1 (fr)
CN (2) CN104837490B (fr)
AP (1) AP2015008441A0 (fr)
AU (1) AU2013358591B2 (fr)
BR (1) BR112015013535A2 (fr)
CA (1) CA2890692A1 (fr)
CL (1) CL2015001610A1 (fr)
CR (1) CR20150314A (fr)
CU (1) CU20150061A7 (fr)
EA (1) EA028673B1 (fr)
ES (1) ES2709034T3 (fr)
HK (1) HK1209637A1 (fr)
IL (1) IL239244A0 (fr)
IN (1) IN2015DN03998A (fr)
MA (1) MA38157A1 (fr)
MX (1) MX363437B (fr)
PE (1) PE20151062A1 (fr)
PH (1) PH12015501216A1 (fr)
SG (1) SG11201503684WA (fr)
TN (1) TN2015000262A1 (fr)
WO (1) WO2014091446A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151062A1 (es) 2012-12-13 2015-08-05 Novartis Ag PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO
WO2015186061A1 (fr) * 2014-06-03 2015-12-10 Novartis Ag Dérivés de pyridopyrimidinedione
CN106459043B (zh) * 2014-06-03 2018-12-28 诺华股份有限公司 萘啶二酮衍生物
EP3152208B1 (fr) 2014-06-03 2019-05-08 Novartis AG Pyrimido [4,5-b]quinoline-4,5(3h, 10h)-diones comme suppresseur de mutations non-sens
CN109152747A (zh) * 2016-04-15 2019-01-04 Uab研究基金会 用于刺激提前终止密码子的通读的方法和化合物
EP3762383B1 (fr) * 2018-03-06 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Modulateurs allostériques positifs du récepteur de la dopamine 1 et procédé d'utilisation associé
WO2019225625A1 (fr) * 2018-05-23 2019-11-28 京都薬品工業株式会社 Inducteur de translecture et utilisation pharmaceutique associée
CA3192236A1 (fr) 2020-09-10 2022-03-17 Tony Lahoutte Fragment d'anticorps contre fap
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス, インコーポレイテッド イソインドリノン化合物
WO2023203135A1 (fr) 2022-04-22 2023-10-26 Precirix N.V. Anticorps radiomarqué amélioré
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024194607A1 (fr) 2023-03-17 2024-09-26 Tay Therapeutics Limited Dérivés de pyrimido[4,5-b][1,5]naphtyridine-4,5(3h,10h)-dione pour le traitement de maladies associées à des mutations ptc, telles que par exemple le cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) * 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ 5−デアザフラビン系化合物を有効成分とする制癌剤
US5908930A (en) * 1995-03-15 1999-06-01 Pfizer Inc. 5,10-dihydropyrimdo 4,5-b!quinolin-4(1H)-one tyrosine kinase inhibitors
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
CA2514733A1 (fr) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Compositions pharmaceutiques a base d'un co-cristal
ES2887054T3 (es) 2003-04-11 2021-12-21 Ptc Therapeutics Inc Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades
DK2390255T3 (en) 2006-04-03 2016-11-07 Technion Res & Dev Foundation Novel aminoglycosides and uses thereof in the treatment of genetic disorders
EP2061470A4 (fr) 2006-08-23 2010-10-06 Neurogen Corp Dérivés de la pyrimidinone substitués par un halogénoalkyle
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (fr) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Conjugués flavine-ligand d'acide nucléique
WO2012016930A1 (fr) 2010-08-05 2012-02-09 Universite De Droit Et Sante De Lille Composé utile pour le traitement de maladies médiées par une mutation non-sens et composition pharmaceutique comprenant ledit composé
PE20151062A1 (es) 2012-12-13 2015-08-05 Novartis Ag PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACION SIN SENTIDO

Also Published As

Publication number Publication date
SG11201503684WA (en) 2015-06-29
CL2015001610A1 (es) 2015-08-07
CA2890692A1 (fr) 2014-06-19
HK1209637A1 (en) 2016-04-08
JP2016503003A (ja) 2016-02-01
WO2014091446A1 (fr) 2014-06-19
MA38157A1 (fr) 2016-12-30
MX363437B (es) 2019-03-22
US20170266189A1 (en) 2017-09-21
BR112015013535A2 (pt) 2017-07-11
PE20151062A1 (es) 2015-08-05
PH12015501216A1 (en) 2015-08-17
CN107569487A (zh) 2018-01-12
AU2013358591B2 (en) 2016-08-25
EA028673B1 (ru) 2017-12-29
CR20150314A (es) 2015-08-10
CN104837490A (zh) 2015-08-12
ES2709034T3 (es) 2019-04-12
CN104837490B (zh) 2017-10-03
AU2013358591A1 (en) 2015-05-28
EA201591105A1 (ru) 2015-10-30
TN2015000262A1 (en) 2016-10-03
US20150335646A1 (en) 2015-11-26
EP2931282A1 (fr) 2015-10-21
AP2015008441A0 (en) 2015-05-31
CU20150061A7 (es) 2015-12-23
JP6076498B2 (ja) 2017-02-08
MX2015007562A (es) 2015-10-14
KR101760586B1 (ko) 2017-07-21
KR20150092306A (ko) 2015-08-12
IL239244A0 (en) 2015-07-30
EP2931282B1 (fr) 2018-10-31
US9649314B2 (en) 2017-05-16

Similar Documents

Publication Publication Date Title
IN2014DN10449A (fr)
NZ608116A (en) Triazine-oxadiazoles
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015501083B1 (en) Novel pyridine derivatives
PH12013501600A1 (en) Novel heterocyclic derivatives
IN2014DN01629A (fr)
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12015501843A1 (en) Novel pyrazol derivatives
IN2015DN01119A (fr)
MY174000A (en) Novel pyridine derivatives
PH12018501709A1 (en) Naphthridinedione derivatives
MX362879B (es) Usos novedosos.
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
IN2014DN10669A (fr)
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX363458B (es) Nuevos derivados de tetrazolona.
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
PH12015500373B1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
TN2013000089A1 (en) Triazine-oxadiazoles
MA37778A1 (fr) Dérivés de carbamate/urée
TN2013000327A1 (en) Novel heterocyclic derivatives